Cancer Research Cancer Epigenetics  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hoang, C. D.
Right arrow Articles by Kratzke, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoang, C. D.
Right arrow Articles by Kratzke, R. A.
[Cancer Research 64, 7479-7485, October 15, 2004]
© 2004 American Association for Cancer Research


Regular Articles

Selective Activation of Insulin Receptor Substrate-1 and -2 in Pleural Mesothelioma Cells

Association with Distinct Malignant Phenotypes

Chuong D. Hoang1, Xihong Zhang2, Paul D. Scott1, Tenner J. Guillaume1, Michael A. Maddaus1, Douglas Yee2 and Robert A. Kratzke2

1 Division of Cardiovascular and Thoracic Surgery, Department of Surgery, and 2 Division of Hematology, Oncology, and Transplant, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota

Molecular mechanisms active in transforming human pleural cells remain incompletely understood. Our previous microarray analysis of malignant pleural mesothelioma revealed alterations in components of the insulin-like growth factor (IGF) system, implicating this signaling axis in tumorigenesis. Therefore, in this current study, we characterized the molecular phenotype and investigated the key signaling pathways of the IGF system in malignant pleural mesothelioma specimens. For the major IGF components, we assessed mRNA abundance and total protein levels. We measured IGF-I ligand-dependent activation of signaling pathways downstream of the type I IGF receptor in a subset of malignant pleural mesothelioma cell lines and determined the corresponding biological consequences. At the transcriptional level, we observed consistent changes in IGF components that may contribute to a malignant phenotype. IGF-I stimulation of cells resulted in enhanced activation of type I IGF receptor and IRS adaptor proteins. Differential activation of IRS-1 signaling was associated with cell growth, whereas IRS-2 signaling was associated with cell motility. Thus, these data suggest that multiple mechanisms likely contribute to malignant pleural mesothelioma tumorigenesis. Therefore, IGF system components represent novel malignant pleural mesothelioma therapeutic targets for investigation.




This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
J.-E. Choi, S.-s. Lee, D. A. Sunde, I. Huizar, K. L. Haugk, V. J. Thannickal, R. Vittal, S. R. Plymate, and L. M. Schnapp
Insulin-like Growth Factor-I Receptor Blockade Improves Outcome in Mouse Model of Lung Injury
Am. J. Respir. Crit. Care Med., February 1, 2009; 179(3): 212 - 219.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
Y. H. Ibrahim, S. A. Byron, X. Cui, A. V. Lee, and D. Yee
Progesterone Receptor-B Regulation of Insulin-Like Growth Factor-Stimulated Cell Migration in Breast Cancer Cells via Insulin Receptor Substrate-2
Mol. Cancer Res., September 1, 2008; 6(9): 1491 - 1498.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
P. Bertino, C. Porta, D. Barbone, S. Germano, S. Busacca, S. Pinato, G. Tassi, R. Favoni, G. Gaudino, and L. Mutti
Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed
Thorax, August 1, 2007; 62(8): 690 - 695.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
Z. Ma, S. L. Gibson, M. A. Byrne, J. Zhang, M. F. White, and L. M. Shaw
Suppression of Insulin Receptor Substrate 1 (IRS-1) Promotes Mammary Tumor Metastasis
Mol. Cell. Biol., December 15, 2006; 26(24): 9338 - 9351.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
B. A. Whitson, B. A. Jacobson, S. Frizelle, M. R. Patel, D. Yee, M. A. Maddaus, and R. A. Kratzke
Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma.
Ann. Thorac. Surg., September 1, 2006; 82(3): 996 - 1001.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Jagadeeswaran, P. C. Ma, T. Y. Seiwert, S. Jagadeeswaran, O. Zumba, V. Nallasura, S. Ahmed, R. Filiberti, M. Paganuzzi, R. Puntoni, et al.
Functional Analysis of c-Met/Hepatocyte Growth Factor Pathway in Malignant Pleural Mesothelioma
Cancer Res., January 1, 2006; 66(1): 352 - 361.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.